Trevi Therapeutics, Inc. (TRVI)

♥ 456 Thanks from members

Trevi Therapeutics, Inc. (TRVI) exhibits strong bullish market sentiment driven by its late-stage clinical progress with Haduvio in chronic cough indications, a robust cash position funding operations into 2030, and key institutional endorsements.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Scientific Founders Leadership: Jennifer Good (President and CEO) Holder: Baker Bros. Advisors Holder: FMR LLC Holder: BlackRock, Inc. Haduvio (nalbuphine ER) #TRVI #Trevi Therapeutics #Biotech #Haduvio #Clinical Stage Pharma